Imarikiren hydrochloride
Tier C — Watch / tradeImarikiren hydrochloride
Targets:REN
Indications (approved):Hypertension, Diabetic nephropathy, Hepatic function decline, Renal impairment
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| IMARIK-001 | 499-81-0 | pyridine-3,5-dicarboxylic acid |
| IMARIK-002 | 4591-55-3 | dimethyl pyridine-3,5-dicarboxylate |
| IMARIK-003 | 595555-70-7 | 1-(tert-butyl) 3,5-dimethyl piperidine-1,3,5-tricarboxylate |
| IMARIK-004 | 191544-71-5 | 1-(tert-butoxycarbonyl)-5-(methoxycarbonyl)piperidine-3-carboxylic acid |
| IMARIK-005 | 534572-28-6 | (3S,5R)-1-(tert-butoxycarbonyl)-5-(methoxycarbonyl)piperidine-3-carboxylic acid |
| IMARIK-006 | - | 1-(tert-butyl) 3-methyl (3R,5S)-5-isocyanatopiperidine-1,3-dicarboxylate |
| IMARIK-007 | 1145747-61-0 | 1-(tert-butyl) 3-methyl (3R,5S)-5-(((benzyloxy)carbonyl)amino)piperidine-1,3-dicarboxylate |
| IMARIK-008 | 191544-79-3 | 1-(tert-butyl) 3-methyl (3R,5S)-5-aminopiperidine-1,3-dicarboxylate |
| IMARIK-009 | 1145745-30-7 | 1-(tert-butyl) 3-methyl (3R,5S)-5-(isobutylamino)piperidine-1,3-dicarboxylate |
| IMARIK-010 | 3584-65-4 | 2-(trichloromethyl)-1H-benzo[d]imidazole |
| IMARIK-011 | 1202261-55-9 | 1-(tert-butyl) 3-methyl (3R,5S)-5-(N-isobutyl-1H-benzo[d]imidazole-2-carboxamido)piperidine-1,3-dicarboxylate |
| IMARIK-012 | 823226-17-1 | 4-methoxybutyl methanesulfonate |
| IMARIK-013 | 1202261-60-6 | 1-(tert-butyl) 3-methyl (3R,5S)-5-(N-isobutyl-1-(4-methoxybutyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-1,3-dicarboxylate |
| IMARIK-014 | 1202261-65-1 | (3R,5S)-1-(tert-butoxycarbonyl)-5-(N-isobutyl-1-(4-methoxybutyl)-1H-benzo[d]imidazole-2-carboxamido)piperidine-3-carboxylic acid |
| IMARIK-015 | 1202261-27-5 | tert-butyl (3S,5R)-3-(N-isobutyl-1-(4-methoxybutyl)-1H-benzo[d]imidazole-2-carboxamido)-5-(morpholine-4-carbonyl)piperidine-1-carboxylate |
| Imarikiren | 1202265-63-1 | N-isobutyl-1-(4-methoxybutyl)-N-((3S,5R)-5-(morpholine-4-carbonyl)piperidin-3-yl)-1H-benzo[d]imidazole-2-carboxamide |
| Imarikiren Hydrochloride | 1202269-24-6 | N-isobutyl-1-(4-methoxybutyl)-N-((3S,5R)-5-(morpholine-4-carbonyl)piperidin-3-yl)-1H-benzo[d]imidazole-2-carboxamide hydrochloride |
| Code | CAS No. | Intermediate |
|---|---|---|
| IMARIK-001 | 499-81-0 | pyridine-3,5-dicarboxylic acid |
| IMARIK-002 | 4591-55-3 | dimethyl pyridine-3,5-dicarboxylate |
| IMARIK-005 | 534572-28-6 | (3S,5R)-1-(tert-butoxycarbonyl)-5-(methoxycarbonyl)piperidine-3-carboxylic acid |
| IMARIK-006 | - | 1-(tert-butyl) 3-methyl (3R,5S)-5-isocyanatopiperidine-1,3-dicarboxylate |
| IMARIK-007 | 1145747-61-0 | 1-(tert-butyl) 3-methyl (3R,5S)-5-(((benzyloxy)carbonyl)amino)piperidine-1,3-dicarboxylate |
| IMARIK-015 | 1202261-27-5 | tert-butyl (3S,5R)-3-(N-isobutyl-1-(4-methoxybutyl)-1H-benzo[d]imidazole-2-carboxamido)-5-(morpholine-4-carbonyl)piperidine-1-carboxylate |
| IMARIK-016 | 920297-39-8 | 1-(tert-butoxycarbonyl)piperidine-3,5-dicarboxylic acid |
| IMARIK-017 | - | tert-butyl (1S,5S)-2,4-dioxo-3-oxa-7-azabicyclo[3.3.1]nonane-7-carboxylate |
| IMARIK-018 | 1352612-42-0 | (R)-1-phenylethan-1-amine (3S,5R)-1-(tert-butoxycarbonyl)-5-(methoxycarbonyl)piperidine-3-carboxylate |
| IMARIK-019 | 1145747-62-1 | (3R,5S)-5-(((benzyloxy)carbonyl)amino)-1-(tert-butoxycarbonyl)piperidine-3-carboxylic acid |
| IMARIK-020 | 1145747-63-2 | tert-butyl (3S,5R)-3-(((benzyloxy)carbonyl)amino)-5-(morpholine-4-carbonyl)piperidine-1-carboxylate |
| IMARIK-021 | 1352612-43-1 | tert-butyl (3S,5R)-3-(isobutylamino)-5-(morpholine-4-carbonyl)piperidine-1-carboxylate succinate |
| IMARIK-022 | 1202269-25-7 | 1-(4-methoxybutyl)-2-(trichloromethyl)-1H-benzo[d]imidazole |
| IMARIK-023 | 88-74-4 | 2-nitroaniline |
| IMARIK-024 | 17913-18-7 | 1-chloro-4-methoxybutane |
| IMARIK-025 | 1248616-01-4 | N-(4-methoxybutyl)-2-nitroaniline |
| IMARIK-026 | 1202261-23-1 | N1-(4-methoxybutyl)benzene-1,2-diamine |
| IMARIK-027 | 2533-69-9 | methyl 2,2,2-trichloroacetimidate |
| Imarikiren | 1202265-63-1 | N-isobutyl-1-(4-methoxybutyl)-N-((3S,5R)-5-(morpholine-4-carbonyl)piperidin-3-yl)-1H-benzo[d]imidazole-2-carboxamide |
| Imarikiren Hydrochloride | 1202269-24-6 | N-isobutyl-1-(4-methoxybutyl)-N-((3S,5R)-5-(morpholine-4-carbonyl)piperidin-3-yl)-1H-benzo[d]imidazole-2-carboxamide hydrochloride |
Frequently asked questions
What are the approved indications of Imarikiren hydrochloride?
Approved indications include: Hypertension, Diabetic nephropathy, Hepatic function decline, Renal impairment.
When does the Imarikiren hydrochloride patent expire?
No public expiry year is available for Imarikiren hydrochloride yet; this page updates once verified.
How many synthesis routes are recorded for Imarikiren hydrochloride?
2 synthesis routes are recorded; the shortest is 14 steps with 2.6 g total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Imarikiren hydrochloride intermediates?
All intermediates in Imarikiren hydrochloride routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for Imarikiren hydrochloride intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09